Joint Development with Korea Italy AAT Institute
Expansion of Overseas Sales Network... Expected Sales of 12 Billion Won This Year
DXVX announced on the 8th that it has entered a full-scale sales growth cycle as its microbiome-based Dx&Vx adjunct therapy lineup, jointly developed with the KoriItaly AAT Research Institute and locally produced and sold in Italy, Korea, and China, has been completed.
The Dx&Vx adjunct therapy products were developed over three years by Dr. Marina's team at the KoriItaly AAT Research Institute. These products are a new concept of health functional foods based on clinically validated microbiome-based products for 12 diseases, assisting in disease prevention as well as mild and severe treatment. Currently, six products focusing on immune enhancement, cognitive improvement, blood circulation improvement, blood sugar improvement, and liver care have been launched and are sold in Korea, Europe, and China. By the third quarter, six additional products targeting colds, menopause, and vaginal health will be released, completing the lineup.
Since the official sales launch in the domestic market in May, approximately 1 billion KRW in sales have been recorded over two months. Sales are being activated through the already established online business division's own sales network, and from the third quarter, distribution channels will expand through medical channels centered on hospitals and pharmacies, as well as overseas markets such as China, Southeast Asia, and Japan. It is expected that sales will reach about 12 billion KRW this year and exceed 36 billion KRW in 2025.
CEO Lee Yong-gu stated, “Since the pandemic, the health management paradigm has shifted to self-prevention. Dx&Vx adjunct therapy products will serve not only as prevention and adjunct treatment for frequently occurring diseases throughout the life cycle but also as a solution to help reduce medical expenses for middle-aged and elderly chronic disease patients entering an aging society.”
He added, “In particular, the KoriItaly AAT Research Institute and KoriChina Microbiome Research Institute have conducted the registration of the MamiAi strain license required by Beijing Hanmi Pharmaceutical from the Chinese CFDA and the approval for local production facilities for strain cultivation and production, solving Hanmi Pharmaceutical’s 20-year long-cherished project. They possess world-class researchers and R&D capabilities related to ‘strains.’”
Meanwhile, DXVX operates with a localization strategy by locally producing and selling the family nutrition brand Ofmom and the Dx&Vx series for prevention and adjunct treatment of frequently occurring diseases throughout the life cycle. Currently, as the healthcare business grows both quantitatively and qualitatively, the company is transforming into a new drug development and digital healthcare company with a cash cow business. It has set targets of 70 billion KRW this year and 500 billion KRW in 2025.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
